サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1702371

左室補助人工心臓（LVAD）の世界市場：2025年～2033年

Global Left Ventricular Assist Device (LVAD) Market - 2025-2033

出版日
ページ情報
英文 198 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
左室補助人工心臓（LVAD）の世界市場：2025年～2033年
出版日: 2025年04月10日
発行: DataM Intelligence
ページ情報: 英文 198 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

世界の左室補助人工心臓（LVAD）の市場規模は、2024年に13億1,000万米ドルに達し、2033年には26億7,000万米ドルに達すると予測され、予測期間の2025年～2033年のCAGRは8.3%となる見込みです。

左室補助人工心臓（LVAD）は、酸素を含んだ血液を全身に送り出す役割を担う左心室が衰弱し、自力でその機能を果たせなくなった場合に、患者の心臓の機能をサポートするために使用される機械式ポンプです。LVADは通常、重度の心不全患者、特に薬物療法や他の治療法では管理できない患者に使用されます。

LVADは、心臓移植を待つ患者さんの一時的な解決策として使用されることが多く、特に心機能が機械的補助なしでは待てないほど悪化している場合に使用されます。心臓移植の候補とならない患者（年齢、合併症、その他の要因による）にとって、LVADは重症心不全を管理するための長期的または永続的な解決策（目的地療法）として機能します。

LVAD技術の進歩が左室補助人工心臓市場の成長を大きく後押ししています。

拍動流LVADから連続流LVADへの移行は、LVAD技術のゲームチェンジャーとなっています。連続流装置は、拍動流装置に比べて信頼性が高く、部品点数が少なく、機械的故障が起こりにくいです。例えば、ハートメイト3 LVAD（Abbott製）は、持続流型人工心臓ですが、患者の予後が大幅に改善しました。臨床試験において、HeartMate 3を使用した患者は、旧式の拍動式人工心臓を使用した患者と比較して、生存率が向上し、合併症が少ないことが明らかになっています。

LVADの小型化は、より小型で効率的な装置の開発につながっています。これらの装置は移植がより容易で、侵襲的な処置がより少なく、患者の移動性がより良好です。生体適合材料の改良により、感染や凝固などの合併症が大幅に減少しました。最新のLVADは、血栓症（血の塊）のリスクを最小限に抑える高度な血液接触材料を使用しており、患者の転帰をより良いものにしています。技術的改善により、より優れた密封技術や改良された駆動系設計がもたらされ、感染や装置の故障のリスクが減少しています。

左室補助人工心臓（LVAD）は末期心不全患者の救命ソリューションであることが証明されていますが、外科的植え込み手術の複雑さが、これらの装置を広く普及させる上で依然として大きな障壁となっています。植え込みプロセスには非常に複雑な手術が含まれ、いくつかのリスクがあるため、特に資源に乏しい医療環境や専門性の低い医療環境では、LVADの使用を拡大することが課題となっています。

LVADの植え込みは非常に複雑な手術で、心臓と循環系の両方に装置を接続するため、かなりの専門知識を必要とします。侵襲的な手術であるため、感染症、出血、血栓症（血の塊）、装置の故障などの合併症のリスクが高いです。

合併症のリスクが高いため、患者の罹患率や入院期間が増加し、患者もヘルスケアプロバイダーもLVADの移植を選択することに慎重になります。このため、特に健康状態がすでに脆弱な合併症のある患者では、LVADの導入が制限されます。LVAD植え込み後の回復過程は長く、感染、出血、ポンプの故障などの合併症がないか常に監視する必要があります。患者はまた、血栓を予防するために、抗凝固療法を含む術後の厳格なレジメンに従う必要があります。

当レポートでは、世界の左室補助人工心臓（LVAD）市場について調査し、市場の概要とともに、製品タイプ別、用途別、エンドユーザー別、地域別動向、競合情勢、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 市場のイントロダクションと範囲

第2章 経営者の洞察と重要なポイント

第3章 市場力学

  • 影響要因
    • 促進要因
    • 抑制要因
    • 機会
    • 影響分析

第4章 戦略的洞察と業界見通し

  • 市場のリーダーとパイオニア
  • 最新の開発とブレークスルー
  • 規制と償還の情勢
  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 特許分析
  • SWOT分析
  • アンメットニーズとギャップ
  • 市場参入と拡大のための推奨戦略
  • シナリオ分析ベストケース、ベースケース、ワーストケースの予測
  • 価格分析と価格動向
  • キーオピニオンリーダー

第5章 左室補助人工心臓（LVAD）市場、製品タイプ別

  • 連続流
  • 拍動流

第6章 左室補助人工心臓（LVAD）市場、用途別

  • BTT
  • DT
  • BTR

第7章 左室補助人工心臓（LVAD）市場、エンドユーザー別

  • 病院
  • 専門心臓クリニック
  • 外来手術センター
  • その他

第8章 左室補助人工心臓（LVAD）市場、地域別市場分析と成長機会

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • スペイン
    • イタリア
    • その他
  • 南米
    • ブラジル
    • アルゼンチン
    • その他
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • 韓国
    • その他
  • 中東・アフリカ

第9章 競合情勢と市場ポジショニング

  • 競合状況の概要と主要市場参入企業
  • 市場シェア分析とポジショニングマトリックス
  • 戦略的パートナーシップ、合併・買収
  • 製品ポートフォリオとイノベーションにおける主な発展
  • 企業ベンチマーク

第10章 企業プロファイル

  • Abbott
    • 会社概要
    • 製品ポートフォリオ
    • 財務概要
    • 主な発展
    • SWOT分析
  • CorWave SA
  • Berlin Heart
  • LivaNova, Inc.
  • Evaheart, Inc.
  • BrioHealth Solutions

第11章 仮定と調査手法

第12章 付録

目次
Product Code: MD2890

The global left ventricular assist device (LVAD) market size reached US$ 1.31 billion in 2024 and is expected to reach US$ 2.67 billion by 2033, growing at a CAGR of 8.3% during the forecast period 2025-2033.

A Left Ventricular Assist Device (LVAD) is a mechanical pump used to support the function of a patient's heart when the left ventricle, responsible for pumping oxygenated blood throughout the body, is too weak to do so on its own. LVADs are typically used in patients with severe heart failure, particularly those whose condition cannot be managed by medication or other therapies.

LVADs are often used as a temporary solution for patients awaiting a heart transplant, especially when their heart function has deteriorated to a point where they cannot wait without mechanical support. For patients who are not candidates for a heart transplant (due to age, comorbidities, or other factors), LVADs can serve as a long-term or permanent solution (destination therapy) to manage severe heart failure.

Market Dynamics: Drivers & Restraints

Rising advancements in LVAD technology are significantly driving the left ventricular assist device market growth.

The shift from pulsatile-flow LVADs to continuous-flow LVADs has been a game-changer in LVAD technology. Continuous-flow devices are more reliable, have fewer parts, and are less prone to mechanical failure compared to pulsatile-flow devices. For instance, the HeartMate 3 LVAD (Abbott), a continuous-flow device, has shown significant improvement in patient outcomes. In clinical trials, it was found that patients with HeartMate 3 experienced better survival rates and fewer complications compared to those with older pulsatile-flow devices.

Miniaturization of LVADs has led to the development of smaller, more efficient devices. These devices are easier to implant, require less invasive procedures, and offer better mobility for patients. Improvements in biocompatible materials have significantly reduced complications like infection and clotting. Modern LVADs use advanced blood-contact materials that minimize the risk of thrombosis (blood clots), leading to better patient outcomes. Technological improvements have led to better sealing technologies and improved driveline designs, reducing the risk of infections and device malfunctions.

Complexity of surgical implantation is hampering the market growth

While left ventricular assist devices (LVADs) have proven to be life-saving solutions for patients with end-stage heart failure, their surgical implantation complexity remains a significant barrier to the broader adoption of these devices. The implantation process involves highly intricate surgeries and poses several risks, making it a challenge to scale the use of LVADs, particularly in resource-constrained or less-specialized healthcare settings.

LVAD implantation is a highly complex surgery that requires significant expertise as it involves connecting the device to both the heart and the circulatory system. Due to the invasive nature of the procedure, there is a high risk of complications such as infection, bleeding, thrombosis (blood clots), and device malfunctions.

The high risk of complications increases patient morbidity and hospitalization time, making both patients and healthcare providers more cautious about opting for LVAD implantation. This, in turn, limits the adoption of LVADs, especially in patients with additional comorbidities who are already in a fragile state of health. The recovery process following LVAD implantation is lengthy and requires constant monitoring for complications like infection, bleeding, or pump malfunction. Patients also need to follow a strict post-operative regimen, including anticoagulation therapy, to prevent blood clots.

Segment Analysis

The global left ventricular assist device (LVAD) market is segmented based on product type, application, end-user, and region.

Product Type:

The continuous flow LVAD segment is expected to dominate the left ventricular assist device market with the highest market share.

The continuous flow left ventricular assist device is the dominant segment within the LVAD market due to its superior performance, improved patient outcomes, and advancements in technology. Unlike traditional pulsatile-flow LVADs, which mimic the heart's natural pumping action, continuous-flow LVADs provide a steady, continuous flow of blood, offering several advantages that contribute to their growing adoption and market dominance.

Continuous flow LVADs offer better clinical outcomes compared to pulsatile flow devices, particularly in terms of survival rates, reduced complication risks, and long-term device performance. For instance, the HeartMate 3 LVAD, a continuous flow device from Abbott, has shown outstanding results in clinical trials. In the MOMENTUM 3 study, the HeartMate 3 demonstrated an 82.8% survival rate at two years, a significant improvement over the pulsatile flow HeartMate II.

Continuous flow LVADs are more compact and efficient than pulsatile devices, offering significant benefits in terms of device size, weight, and reliability. Continuous flow devices typically have a longer operational life and fewer moving parts, which reduces the likelihood of mechanical failure. As a result, patients with continuous flow LVADs often experience more consistent heart function and better quality of life. Continuous flow LVADs have been shown to carry a lower risk of complications such as pump thrombosis, stroke, and infection, which are often associated with pulsatile devices.

Geographical Analysis

North America is expected to hold a significant position in the global left ventricular assist device market with the highest market share

North America, particularly the United States and Canada, is the leading region in the LVAD market due to its strong healthcare infrastructure, high prevalence of heart failure, advanced medical technology, regulatory approvals, and favorable reimbursement policies. The region accounts for the largest market share globally, with significant contributions from key players like Abbott, Medtronic, and others.

The growing number of heart failure (HF) cases in North America is a major factor driving LVAD adoption. For instance, according to the National Institute of Health (NIH), approximately 6.7 million Americans over 20 years of age have HF, and the prevalence is expected to rise to 8.5 million Americans by 2030. The lifetime risk of HF has increased to 24%; approximately 1 in 4 persons will develop HF in their lifetime. The increasing number of patients with end-stage heart failure has led to a higher demand for LVADs as both Bridge-to-Transplant (BTT) and Destination Therapy (DT).

North America is home to leading LVAD manufacturers, which contribute to rapid product innovations and market growth. For instance, Abbott's HeartMate 3, a continuous flow LVAD, has become the gold standard in mechanical circulatory support.

Competitive Landscape

Top companies in the left ventricular assist device (LVAD) market include Abbott, CorWave SA, Berlin Heart, LivaNova, Inc., Evaheart, Inc., and BrioHealth Solutions, among others.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyze product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: This covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyze competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global left ventricular assist device (LVAD) market report delivers a detailed analysis with 50 key tables, more than 48 visually impactful figures, and 198 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

  • 1.1. Objectives of the Report
  • 1.2. Report Coverage & Definitions
  • 1.3. Report Scope

2. Executive Insights and Key Takeaways

  • 2.1. Market Highlights and Strategic Takeaways
  • 2.2. Key Trends and Future Projections
  • 2.3. Snippet by Product Type
  • 2.4. Snippet by Application
  • 2.5. Snippet by End-User
  • 2.6. Snippet by Region

3. Dynamics

  • 3.1. Impacting Factors
    • 3.1.1. Drivers
      • 3.1.1.1. Rising Advancements in LVAD Technology
      • 3.1.1.2. Increasing Prevalence of Heart Failure
    • 3.1.2. Restraints
      • 3.1.2.1. Complexity of Surgical Implantation
      • 3.1.2.2. Risk of Device Rejection and Incompatibility
    • 3.1.3. Opportunity
      • 3.1.3.1. Miniaturization and Next-Generation LVADs
    • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

  • 4.1. Market Leaders and Pioneers
    • 4.1.1. Emerging Pioneers and Prominent Players
    • 4.1.2. Established Leaders with Largest Marketing Brand
    • 4.1.3. Market Leaders with Established Products
  • 4.2. Latest Developments and Breakthroughs
  • 4.3. Regulatory and Reimbursement Landscape
    • 4.3.1. North America
    • 4.3.2. Europe
    • 4.3.3. Asia Pacific
    • 4.3.4. South America
    • 4.3.5. Middle East & Africa
  • 4.4. Porter's Five Forces Analysis
  • 4.5. Supply Chain Analysis
  • 4.6. Patent Analysis
  • 4.7. SWOT Analysis
  • 4.8. Unmet Needs and Gaps
  • 4.9. Recommended Strategies for Market Entry and Expansion
  • 4.10. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 4.11. Pricing Analysis and Price Dynamics
  • 4.12. Key Opinion Leaders

5. Left Ventricular Assist Device (LVAD) Market, By Product Type

  • 5.1. Introduction
    • 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 5.1.2. Market Attractiveness Index, By Product Type
  • 5.2. Continuous Flow LVAD*
    • 5.2.1. Introduction
    • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 5.3. Pulsatile Flow LVAD

6. Left Ventricular Assist Device (LVAD) Market, By Application

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 6.1.2. Market Attractiveness Index, By Application
  • 6.2. Bridge to Transplant (BTT)*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Destination Therapy (DT)
  • 6.4. Bridge to Recovery (BTR)

7. Left Ventricular Assist Device (LVAD) Market, By End-User

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 7.1.2. Market Attractiveness Index, By End-User
  • 7.2. Hospitals*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Specialty Cardiac Clinics
  • 7.4. Ambulatory Surgical Centers
  • 7.5. Others

8. Left Ventricular Assist Device (LVAD) Market, By Regional Market Analysis and Growth Opportunities

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 8.1.2. Market Attractiveness Index, By Region
  • 8.2. North America
    • 8.2.1. Introduction
    • 8.2.2. Key Region-Specific Dynamics
    • 8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.2.6.1. U.S.
      • 8.2.6.2. Canada
      • 8.2.6.3. Mexico
  • 8.3. Europe
    • 8.3.1. Introduction
    • 8.3.2. Key Region-Specific Dynamics
    • 8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.3.6.1. Germany
      • 8.3.6.2. UK
      • 8.3.6.3. France
      • 8.3.6.4. Spain
      • 8.3.6.5. Italy
      • 8.3.6.6. Rest of Europe
  • 8.4. South America
    • 8.4.1. Introduction
    • 8.4.2. Key Region-Specific Dynamics
    • 8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.4.6.1. Brazil
      • 8.4.6.2. Argentina
      • 8.4.6.3. Rest of South America
  • 8.5. Asia-Pacific
    • 8.5.1. Introduction
    • 8.5.2. Key Region-Specific Dynamics
    • 8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.5.6.1. China
      • 8.5.6.2. India
      • 8.5.6.3. Japan
      • 8.5.6.4. South Korea
      • 8.5.6.5. Rest of Asia-Pacific
  • 8.6. Middle East and Africa
    • 8.6.1. Introduction
    • 8.6.2. Key Region-Specific Dynamics
    • 8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

9. Competitive Landscape and Market Positioning

  • 9.1. Competitive Overview and Key Market Players
  • 9.2. Market Share Analysis and Positioning Matrix
  • 9.3. Strategic Partnerships, Mergers & Acquisitions
  • 9.4. Key Developments in Product Portfolios and Innovations
  • 9.5. Company Benchmarking

10. Company Profiles

  • 10.1. Abbott*
    • 10.1.1. Company Overview
    • 10.1.2. Product Portfolio
      • 10.1.2.1. Product Description
      • 10.1.2.2. Product Key Performance Indicators (KPIs)
      • 10.1.2.3. Historic and Forecasted Product Sales
      • 10.1.2.4. Product Sales Volume
    • 10.1.3. Financial Overview
      • 10.1.3.1. Company Revenue
      • 10.1.3.2. Geographical Revenue Shares
      • 10.1.3.3. Revenue Forecasts
    • 10.1.4. Key Developments
      • 10.1.4.1. Mergers & Acquisitions
      • 10.1.4.2. Key Product Development Activities
      • 10.1.4.3. Regulatory Approvals, etc.
    • 10.1.5. SWOT Analysis
  • 10.2. CorWave SA
  • 10.3. Berlin Heart
  • 10.4. LivaNova, Inc.
  • 10.5. Evaheart, Inc.
  • 10.6. BrioHealth Solutions

LIST NOT EXHAUSTIVE

11. Assumption and Research Methodology

  • 11.1. Data Collection Methods
  • 11.2. Data Triangulation
  • 11.3. Forecasting Techniques
  • 11.4. Data Verification and Validation

12. Appendix

  • 12.1. About Us and Services
  • 12.2. Contact Us